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XDR-TB in South Africa: 
Back to TB Sanatoria Perhaps?
Ramalitse Sakoane
It is only about 25 years since the abolition or abandonment 
of TB sanatoria in South Africa. It is likely that there are 
people in South Africa who are familiar with the idea of 
isolation of TB patients from the general public emanating 
from the era of TB sanatoria, and it is conceivable that they 
are likely to be understanding of the reasons that were used 
to keep patients there during their treatment.
These people could help to make the idea of isolation in 
sanatoria acceptable again to the general public. Anyway, 
the TB sanatoria of this era were rightfully regarded as 
hospitals, as indeed they were, and I cannot see why modern 
day sanatoria should be viewed any differently. Granted, with 
the likelihood that the patients detained in these envisaged 
isolation areas may be more likely to die than be discharged, 
it will be a mammoth task to convince the “detainees” to 
stay there or their families to allow them to be kept there, 
especially if they are minors or the elderly inﬁ  rm. It is a tough 
call but it is worth a try.
The South African government owes it to the South African 
public to explore this idea or one along these lines. There is 
no time for chickening out on this XDR-TB issue [1].  
Ramalitse Sakoane (r.sakoane@doctors.org.uk) 
Norfolk and Norwich University Hospital 
Norwich, United Kingdom 
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XDR-TB in South Africa: 
Revised Deﬁ  nition
Timothy H. Holtz
The authors should be commended for a thoughtful and 
stimulating article [1]. However, we wish to clarify the 
historical record about the use of the term XDR-TB. The 
concept of XDR-TB as a distinct nosological entity was ﬁ  rst 
developed at the Centers for Disease Control and Prevention 
(CDC) in March 2005 and introduced into public use 
in October 2005 at the 36th World Conference on Lung 
Health in Paris [2,3]. At that meeting, data on second-line 
drug resistance from a global survey of supranational TB 
reference laboratories conducted by CDC and the World 
Health Organization, as well as treatment outcomes of XDR-
TB patients in Latvia, were ﬁ  rst presented. Shortly thereafter, 
the cluster of TB deaths with resistance to second-line drugs 
in HIV-infected persons in KwaZulu-Natal was presented 
at the 13th Conference on Retroviruses and Opportunistic 
Infections in Denver in February 2006 [4]. The original 
deﬁ  nition for XDR-TB published in the Morbidity and Mortality 
Weekly Report in March 2006 [5] that they have used, however, 
was revised in October 2006 at an emergency meeting of 
the Global XDR-TB Task Force. The revised deﬁ  nition was 
published on November 3, 2006 in an MMWR notice to 
readers [6]. Currently, XDR-TB is deﬁ  ned as the occurrence 
of TB in persons whose Mycobacterium tuberculosis isolates are 
resistant to isoniazid and rifampin plus any ﬂ  uoroquinolone 
and at least one of the three injectable second-line drugs 
(amikacin, kanamycin, capreomycin). The deﬁ  nition was 
revised because drug susceptibility testing to these drugs 
produces reliable and reproducible results, and is more 
accessible in resource-limited settings. In addition, patients 
meeting the revised deﬁ  nition have signiﬁ  cantly poorer 
treatment outcomes. The new deﬁ  nition is important for 
those intending to conduct surveillance for XDR-TB in their 
setting.  
Timothy H. Holtz (tholtz@cdc.gov)
Centers for Disease Control and Prevention
Atlanta, Georgia, United States of America. 
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XDR-TB in South Africa: 
Theory and Practice
Jason Andrews, Sanjay Basu, David Scales, 
Duncan Smith-Rohrberg Maru, Ramnath Subbaraman
Singh and colleagues [1] highlight safeguards against the 
spread of XDR-TB and suggest “involuntary detention” as a 
key infection control measure. Yet several important elements 
of the current response to XDR-TB may make the application PLoS Medicine  |  www.plosmedicine.org 0771
of enforced conﬁ  nement ineffective and inappropriate as 
part of the initial response to this problem.
One irony of this discussion is that patients diagnosed with 
drug-resistant TB in KwaZulu-Natal are being turned away 
from the referral hospitals where second-line therapy takes 
place. There is a waiting list of more than 70 patients for 
admission to King George V Hospital, where the majority of 
MDR-TB therapy is provided. Rather than keeping patients 
“in”—the debate posed in this article—the reality is that 
health services are unable to accommodate the burden of 
MDR-TB patients seeking care.
The authors cite United States policies during MDR-TB 
outbreaks as evidence of the success of detention but fail to 
note that US conﬁ  nement measures were rarely invoked. 
The New York City Tuberculosis Working Group concluded: 
“It is unethical, illegal, and bad public health policy to 
detain ‘noncompliant’ persons before making concerted 
efforts to address the numerous systemic deﬁ  ciencies that 
make adherence to treatment virtually impossible” [2]. 
Thus, patients were ﬁ  rst offered directly observed therapy as 
outpatients. Among the few patients cited as non-adherent, 
less than half were detained. Monetary incentives and 
transportation vouchers were provided for outpatients, as well 
as housing to the homeless [3]. In contrast, many MDR-TB 
patients in KwaZulu-Natal must travel several hours monthly 
to receive treatment. 
It is estimated that the South African government will 
spend 15 billion rand (~US$1.9 billion) for the upcoming 
World Cup, much of it for building stadiums [4]. Yet, while 
the largest outbreak of XDR-TB ever recorded is unfolding, 
little appropriate investment has been made. Purchasing 
trailer homes as isolation facilities, providing particulate 
respirator masks in all hospitals, and instituting other basic 
infection control procedures is immediately necessary. 
Framing the debate about forced conﬁ  nement in terms of 
individual liberty versus threat to society neglects the true 
injustice taking place. 
While Singh and colleagues discuss the importance of 
“reciprocity,” they fail to mention the most important 
reciprocity obligation of those instituting conﬁ  nement: 
providing the proper standard of medical care to detained 
patients. At present, many XDR-TB patients are provided 
therapy that includes only two active agents—a recipe for 
ampliﬁ  cation of resistance. While XDR-TB patients elsewhere 
have been successfully treated with other regimens [5], the 
majority of South African patients have yet to access many 
second-line drugs, including capreomycin, moxiﬂ  oxacin, 
para-aminosalicylic acid, or adjunctive thoracic surgery. 
Without these, they are left to die without a ﬁ  ghting chance, 
two years after this outbreak was ﬁ  rst reported. The intent of 
detention in the US was to provide short inpatient stays and 
curative therapy. The median period of detention was three 
weeks, and only 2% of patients died from tuberculosis [3]. In 
South Africa, XDR-TB is nearly universally fatal under current 
treatments, and detention would presumably be sustained 
until death. Our willingness to respond to the realities of 
patient needs, rather than to abstract theories, will determine 
the success of the response to XDR-TB.  
Jason Andrews (jason.andrews@yale.edu) 
Sanjay Basu
David Scales
Duncan Smith-Rohrberg Maru
Ramnath Subbaraman
Yale University School of Medicine
New Haven, Connecticut, United States of America 
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XDR-TB in South Africa: 
Detention Is Not the Priority
Eric Goemaere, Nathan Ford, Daniel Berman, 
Cheryl McDermid, Rachel Cohen
We agree that there is “no time for denial or complacency” 
when it comes to the spread of MDR- and XDR-TB in South 
Africa. Unfortunately, the attention the recent PLoS Medicine 
article [1] generated in South Africa and internationally has 
overwhelmingly focused on detention of patients. Headlines 
such as “South Africa urged to isolate ‘killer’ TB patients” [2] 
place the blame on patients and divert attention from more 
urgent priorities.
The TB epidemic in South Africa, as across sub-Saharan 
Africa, is largely linked to HIV. In Khayelitsha Township near 
Cape Town, new cases had risen to around 2,000 per 100,000 
in 2006, fuelled by the high prevalence of HIV. From our 
experience in South Africa, a number of challenges must be 
addressed locally and nationally to curb MDR-TB. Detention 
does not come high on this list. 
Effective MDR-TB management requires improvements in 
general TB control, but this alone will not remove the need 
to respond to MDR-TB. The Western Cape has the best TB 
outcomes in South Africa, thanks to enormous investments 
in TB control, but despite this MDR- and XDR-TB cases 
are increasingly being reported. There is an urgent priority 
for infection control, taking into account the context of 
limited resources at the primary care level and high HIV 
prevalence. Data from mid-2006 show that 67% of TB patients 
in Khayelitsha are HIV positive; in Médecins Sans Frontières’ 
programme in Lesotho the ﬁ  gure rises to 92%. Patient triage 
is one aspect, but the reality is that undiagnosed MDR- and 
XDR-TB patients with HIV are sitting in overcrowded waiting 
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rooms next to other immunocompromised patients. Personal 
protection for health staff, starting with basic training 
on infection control, needs to be improved. Structural 
improvements to the clinics need to be based on feasible, 
low-tech solutions—air extractors and windows will be more 
practical than UV lights and negative pressure rooms [3]. 
Access to points of care needs to increase. The Western 
Cape has reported over 800 cases of MDR-TB in the last 
two years and this is certainly an underestimation. Greater 
diagnostic capacity and more rapid diagnosis is needed, 
and diagnosis must be met with better access to treatment. 
Treating MDR-TB currently relies on hospitalization of 
patients, but current needs are far greater than hospital 
capacity—patients can wait up to four months for a hospital 
bed. The traditional model of leaving MDR-TB management 
to specialists has incapacitated health-care staff at the primary 
care level who receive little or no training on how to manage 
MDR-TB. In other settings in southern Africa the situation 
is even worse. In Lesotho there is practically no access to 
reliable culture or drug-sensitivity testing. Given the scarcity 
of human resources and the overwhelming number of co-
infected patients, treatment needs to be delivered in as 
decentralized a manner as possible.
In settings where clinics are saturated and patient numbers 
are rising, it is not realistic to rely on a strategy of simply 
reinforcing directly observed treatment and incarcerating 
defaulters to respond to MDR-TB. We need to apply the 
lessons learnt from providing HIV care in resource-poor 
settings, including decentralization of services to the primary 
care level, reinforcing adherence through treatment literacy 
and a patient-centred approach, and community-based 
support. The reality, though, is that an integrated approach 
to HIV and TB is far away: around a third of MDR-TB patients 
in Khayelitsha do not even know their HIV status. 
Drug-resistant TB is not a new problem. What is new is the 
willingness to detect and treat it. The lack of willingness to do 
so until recently has left us with old drugs and diagnostics that 
make treating drug-resistant TB at best highly complex and 
resource intensive, and at worst impossible. Programme-level 
improvements have to be met with a dramatic increase in 
efforts to develop new drugs and diagnostics [4].  
Eric Goemaere (goemaere@mweb.co.za)
Nathan Ford
Daniel Berman
Cheryl McDermid
Rachel Cohen 
Médecins Sans Frontières
Cape Town, South Africa
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Adherence to TB Treatment in 
Ethiopia: Why Do Patients Default?
Hundie Tesfaye
Tuberculosis as a disease has been present in humans 
since antiquity, with the earliest unambiguous detection of 
Mycobacterium tuberculosis in the remains of bison dated 17,000 
years before the present [1]. About 90% of those infected 
with TB have asymptomatic (latent) infection. One in ten 
latent infections may progress to active disease which, if left 
untreated, kills more than half of its victims [2]. In 2004, 
14.6 million people had active TB and there were 8.9 million 
new cases and 1.7 million deaths [3], mostly in developing 
countries, including Ethiopia.
Shargie and Lindtjørn explain the physical lack of 
access to the treatment centre as the main cause of failure 
to adherence to therapy in 20% of patients [4]. Only 52 
patients indicated they lived over 10 km from the treatment 
centre. It is not clear whether all the 52 are among those 
who failed to complete the doses. It was of interest whether 
all 64 patients from the urban area (near to the treatment 
centre) completed the treatment. Nevertheless, it might be 
worthwhile to compare the rate of completion of treatment of 
the 64 urban dwellers with those 52 individuals to support the 
idea that physical access to the treatment centre is the main 
factor for treatment adherence.
Almost half of the patients enrolled in the study earned 
0–99 Ethiopian birr (approximately 0–10 US dollars) per 
month. However, it is not clear from the report whether all 
74 (91%) who failed to complete the treatment belonged 
to those with low monthly income. Furthermore, the fate of 
those earning more than 200 birr (approximately US$20) 
was not clear in terms of treatment completion. The authors 
reported that income had no inﬂ  uence on the outcomes in 
terms of treatment completion, despite their inclusion of cost 
of transport among the factors which led to incompletion of 
therapy.
Unfortunately the study did not evaluate the data of 
family numbers and its inﬂ  uence on treatment adherence 
in relation to family income. Larger family size with 
inappropriate income may contribute to malnutrition, 
leading to drug intolerance and general malaise and ﬁ  nally to 
loss of motivation to continue the treatment course.
The authors stated there was no inﬂ  uence of HIV status on 
the defaulting of treatment, despite the known fact that more 
than half of the cohort studied did not volunteer for the HIV 
test.
Drug-resistant strains of TB have emerged and are 
spreading dangerously. In 2000–2004, 20% of cases were 
resistant to standard treatments, and 2% were also resistant 
to second-line drugs [5]. In spite of only one treatment 
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failure here, extensively drug-resistant TB may be a possible 
challenge in Ethiopia. Whether Ethiopia succeeds in the 
Stop TB Partnership’s Global Plan to Stop Tuberculosis, 
which aims to save 14 million lives between 2006 and 2015 
(see http:⁄⁄www.stoptb.org/globalplan), depends on 
the effectiveness of the national program, infrastructure 
development, peace, and good governance with sustainable 
development assistance from donors directed to improving 
the life condition of the Ethiopian people, so that the 
population is self-sufﬁ  cient and conﬁ  dent enough to 
overcome burning issues like TB.
In conclusion, the study conﬁ  rms that TB drug delivery, 
without implementation of anti-poverty programs and more 
access to public health facilities, is ineffective.  
Hundie Tesfaye (hundie.tesfaye@fnmotol.cz)
University Hospital in Motol, Charles University
Prague, Czech Republic 
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Why Most Published Research Findings 
Are False: Problems in the Analysis
Steven Goodman, Sander Greenland
The article published in PLoS Medicine by Ioannidis [1] makes 
the dramatic claim in the title that “most published research 
claims are false,” and has received extensive attention as a 
result. The article does provide a useful reminder that the 
probability of hypotheses depends on much more than 
just the p-value, a point that has been made in the medical 
literature for at least four decades, and in the statistical 
literature for decades previous. This topic has renewed 
importance with the advent of the massive multiple testing 
often seen in genomics studies.
Unfortunately, while we agree that there are more false 
claims than many would suspect—based both on poor study 
design, misinterpretation of p-values, and perhaps analytic 
manipulation—the mathematical argument in the PLoS 
Medicine paper underlying the “proof” of the title’s claim has 
a degree of circularity. As we show in detail in a separately 
published paper [2], Dr. Ioannidis utilizes a mathematical 
model that severely diminishes the evidential value of 
studies—even meta-analyses—such that none can produce 
more than modest evidence against the null hypothesis, and 
most are far weaker. This is why, in the offered “proof,” the 
only study types that achieve a posterior probability of 50% or 
more (large RCTs [randomized controlled trials] and meta-
analysis of RCTs) are those to which a prior probability of 
50% or more are assigned. So the model employed cannot be 
considered a proof that most published claims are untrue, but 
is rather a claim that no study or combination of studies can 
ever provide convincing evidence.
The two assumptions that produce the above effect are:
1) Calculating the evidential effect only of verdicts of 
“signiﬁ  cance,” i.e., p ≤ 0.05, instead of the actual p-value 
observed in a study, e.g., p = 0.001.
2) Introducing a new “bias” term into the Bayesian 
calculations, which even at a described “minimal” level (of 
10%) has the effect of very dramatically diminishing a study’s 
evidential impact.
In addition to the above problems, the paper claims to 
have proven something it describes as paradoxical; that the 
“hotter” an area is (i.e., the more studies published), the 
more likely studies in that area are to make false claims. We 
have shown this claim to be erroneous [2]. The mathematical 
proof offered for this in the PLoS Medicine paper shows merely 
that the more studies published on any subject, the higher 
the absolute number of false positive (and false negative) 
studies. It does not show what the papers’ graphs and text 
claim, viz, that the number of false claims will be a higher 
proportion of the total number of studies published (i.e., 
that the positive predictive value of each study decreases with 
increasing number of studies).
The paper offers useful guidance in a number of areas, 
calling attention to the importance of avoiding all forms of 
bias, of obtaining more empirical research on the prevalence 
of various forms of bias, and on the determinants of prior 
odds of hypotheses. But the claims that the model employed 
in this paper constitutes a “proof” that most published 
medical research claims are false, and that research in “hot” 
areas is most likely to be false, are unfounded.  
Steven Goodman (sgoodman@jhmi.edu)
Johns Hopkins School of Medicine
Baltimore, Maryland, United States of America
Sander Greenland
University of California Los Angeles
Los Angeles, California, United States of America
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Palladin Mutation Causes Familial 
Pancreatic Cancer: Absence in 
European Families
Emily Slater, Vera Amrillaeva, Volker Fendrich, 
Detlef Bartsch, Julie Earl, Louis J. Vitone, 
John P. Neoptolemos, William Greenhalf
We read with interest the article published in PLoS Medicine 
by Pogue-Geile et al. [1] reporting an apparent mutation in 
the KIAA0992 splice variant of the palladin gene in a family 
previously reported to have a high incidence of pancreatic 
cancer. Pogue-Geile and others had previously established 
that the 4q32–34 locus segregated with pancreatic cancer 
in this family by screening for pre-neoplastic lesions, which 
could then be used as a marker for mutation carriers [2]. In 
the PLoS Medicine paper the authors show that the mutation 
in palladin is on the 4q32–34 haplotype that segregates with 
the disease. The European Registry of Hereditary Pancreatitis 
and Familial Pancreatic Cancer (EUROPAC) and the German 
National Case Collection for Familial Pancreatic Cancer 
(FaPaCa) have recently shown that a mutation on 4q32–34 
is unlikely to explain pancreatic cancer in a majority of our 
European families, but we did not rule out segregation with 
the disease in a minority of families [3]. 
Naturally we were keen to establish if the mutation seen in 
Family X from America was seen in any of our families, and so 
we have sequenced the locus in 74 individuals who were either 
affected by pancreatic cancer or who are obligate carriers 
(assuming autosomal dominant inheritance) of the disease 
mutation (in 74 families). We have also sequenced the locus in 
14 affected individuals from 14 families with familial multiple 
mole melanoma with cases of pancreatic cancer (FAMMM-PC) 
[4] and nine sporadic pancreatic cancer patients of less than 
50 years of age. We did not identify the mutation in any of the 
individuals, neither as a heterozygote or a homozygote. 
This does not of course mean that other mutations in 
coding or non-coding regions of this variant of palladin or 
other variants are absent from European families. However, it 
is noteworthy that the phenotype of Family X is signiﬁ  cantly 
different from the phenotype common to the families on the 
EUROPAC/FaPaCa registries. In particular, the incidence 
of diabetes in our families is relatively low, except where the 
diabetes is a direct consequence of development of cancer 
[3]. This presentation contrasts strongly with the family 
harbouring the palladin mutation [1,2], where diabetes was 
common. It is possible that Family X (and the association with 
palladin mutation) is not typical of the familial pancreatic 
cancer syndrome.  
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Training of Peer Reviewers: 
Validation of a 5-Point Rating Scale
Michael Callaham
We regret that in our paper in the January issue of PLoS 
Medicine [1], we failed to cite an important recent study [2] 
that validates a simple 5-point quality rating score virtually 
identical to the one we used, and which we ﬁ  nd more 
efﬁ  cient than scores with multiple subscales. We apologize for 
the omission of this helpful research.  
Michael Callaham (mlc@medicine.ucsf.edu)
University of California San Francisco
San Francisco, California, United States of America
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PLoS Medicine and Publication Ethics: 
When Is It Research?
Mary Ann Baily
I read this editorial with interest [1]. The issues discussed 
under the heading “Is a Program Description a Research 
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Paper?” are closely related to the subject matter of a recently 
completed Hastings Center project funded by the Agency for 
Healthcare Research and Quality.
The project was carried out by a group of distinguished 
participants with expertise in medicine, law, nursing, quality 
improvement methods, research ethics, medical editing 
and publishing, health services research, and health policy 
and regulation. It addressed the ethics of using quality 
improvement (QI) methods to improve health care quality 
and safety, and we spent considerable time on the vexing 
question of when (if ever) QI activities meet the regulatory 
deﬁ  nition of research and should be submitted to an 
Institutional Review Board (IRB) for ethical review. We also 
discussed the relationship between publication and IRB 
review.
Our analysis would lead to the same conclusion that was 
reached in the editorial: that the particular case example 
was not research and did not require IRB review. Readers 
might ﬁ  nd the report’s reasoning on the issues interesting, 
however—and also useful in assessing other cases.
Both the project report [2] and a book of background 
papers [3] have been published, and they can be downloaded 
in PDF form at no charge from the Web site of The Hastings 
Center (http:⁄⁄www.thehastingscenter.org) or the Institute 
for Healthcare Improvement (http:⁄⁄www.ihi.org).  
Mary Ann Baily (bailym@thehastingscenter.org)
The Hastings Center
Garrison, New York, United States of America
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